Table 1.

– Summary of articles evaluating the outcome of primary RPLND in different clinical stages of testicular germ cell tumors

Reference	No. Pts.	RPLND Template	Adjuvant Chemotherapy (%)	Follow-up (months)	Relapse rate (%)	Death rate (%)
Stage I NSGCT
Richie et al. 1990[14]	85	Unilateral	15	38 (median)	6 PS I; 15 PS II	0
Donohue et al.1993[12]	378*	Bilateral and unilateral	13	71.3 (mean)	12 PS I; 34 PS II without Cx; 0 PS II with Cx	0.8
Hermans et al. 2000[7]	292	NA	12	46 (median)	10 PS I; 23 PS II without Cx; 0 PS II with Cx	0.3
Stephens on et al. 2005[13]	297	Bilateral and unilateral	15	59 (median)	6 PS I; 19 PS II	0
Albers et al. 2008[10]	173	Unilateral	18	56 (median)	9 Overall	0
Stage II NSGCT
Donohue et al. 1995[21]	140*	Bilateral and unilateral	42	132 (mean)	6 PS I; 37 PS II without Cx; 0 PS II with Cx	2
Weissbach et al. 2000[22]	109	Bilateral and unilateral	88	36 (median)	23 PS I; 5 PS II-III with Cx	0
Stephens on et al. 2007[20]	136	Bilateral and unilateral	49	63 (median)	21 overall at 5-year	2 at 5-year
Stage I-II Seminoma
Warszawski et al. 1997[28]	45 CS I; 18 CSII	Bilateral	0	79 (median)	7 PS I, 33 PS II	8 at 5-years
Mezvrishvili etal. 2006[29]	IOCS I; 4 CS II	Unilateral	0	56 (mean)	0	0
Hu et al. 2015[30]	4CS II	Unilateral	0	25 (mean)	0	0

RPLND = retroperitoneal lymph node dissection; NSGCT = non-seminoma germ cell tumor; PS = pathologic stage; Cx = chemotherapy; NA = not available; CS = clinical stage

^*Includes patients treated after 1979.